Clin Gastroenterol Hepatol by Lu, Mei et al.
Serum Biomarkers Indicate Long-term Reduction in Liver 
Fibrosis in Patients With Sustained Virological Response to 
Treatment for HCV Infection
Mei Lu*, Jia Li*, Talan Zhang*, Loralee B. Rupp‡, Sheri Trudeau*, Scott D. Holmberg§, Anne 
C. Moorman§, Philip R. Spradling§, Eyasu H. Teshale§, Fujie Xu§, Joseph A. Boscarino||, 
Mark A. Schmidt¶, Vinutha Vijayadeva#, and Stuart C. Gordon** for the Chronic Hepatitis 
Cohort Study Investigators
*Department of Public Health Sciences, Henry Ford Health System, Detroit, Michigan
‡Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, 
Michigan
**Division of Gastroenterology and Hepatology, Henry Ford Health System, Detroit, Michigan
§Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, 
Centers for Disease Control and Prevention, Atlanta, Georgia
||Center for Health Research, Geisinger Health System, Danville, Pennsylvania
¶Center for Health Research, Kaiser Permanente–Northwest, Portland, Oregon
#Center for Health Research, Kaiser Permanente–Hawai’i, Waipahu, Hawaii
Abstract
BACKGROUND & AIMS—Sustained virological response (SVR) to antiviral therapy for 
hepatitis C virus (HCV) correlates with changes in biochemical measures of liver function. 
However, little is known about the long-term effects of SVR on liver fibrosis. We investigated the 
effects of HCV therapy on fibrosis, based on the Fibrosis-4 (FIB4) score, over a 10-year period.
METHODS—We collected data from participants in the Chronic Hepatitis Cohort Study—a large 
observational multicenter study of patients with hepatitis at 4 US health systems—from January 1, 
2006, through December 31, 2013. We calculated patients’ FIB4 score and the aminotransferase-
to-platelet ratio index (APRI) score over a 10-year period. Of 4731 patients with HCV infection, 
1657 (35%) were treated and 755 (46%) of these patients achieved SVR.
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RESULTS—In propensity score–adjusted analyses, we observed significant longitudinal changes 
in FIB4 score that varied with treatment and response to treatment. In patients achieving SVR, 
FIB4 scores decreased sharply, remaining significantly lower over the 10-year period than in 
untreated patients or patients with treatment failure (P < .001). In independent analyses, men and 
patients with HCV genotype 1 or 3 infections had higher FIB4 scores than women or patients with 
HCV genotype 2 infections (P < .01 for both). Findings were similar in a sensitivity analysis that 
substituted the APRI as the marker of fibrosis instead of the FIB4 score.
CONCLUSIONS—SVR to HCV treatment appears to induce long-term regression of fibrosis 
based on FIB4 scores collected over 10 years from a large observational study of US hepatitis 
patients. Patients receiving no treatment or with treatment failure had progressive increases in 
FIB4 scores.
Keywords
CHeCS; Fibrosis Progression; Growth Curve Analysis of Trajectory; Outcome
The extent to which antiviral therapy for hepatitis C virus (HCV) alters the course of fibrosis 
progression is not well understood. Various studies have described fibrosis progression in 
untreated patients, and several histologic studies have shown improvements in fibrosis after 
sustained virological response (SVR) to therapy.1–7
Although liver biopsy may be used to assess fibrosis, its use is decreasing.8 A noninvasive, 
easily obtained, and inexpensive marker of liver fibrosis may address challenges in 
longitudinal monitoring of HCV patients, especially in large cohorts or when more 
expensive or complex tests—such as liver biopsy and transient elastography—are not 
routinely available. Serum-based markers of fibrosis, including the Fibrosis-4 (FIB4) score 
and the aminotransferase-to-platelet ratio index (APRI), have been validated in controlled 
environments; these measures also are used in clinical trials of antiviral treatments. We have 
further validated these markers in the Chronic Hepatitis Cohort Study (CHeCS) HCV 
population; the validated area under the receiver operator characteristic curve was 0.83 to 
0.85 for FIB4 and 0.80 to 0.81 for APRI.9,22 Changes in FIB4 have been shown to correlate 
with changes in liver fibrosis stage over time in HCV patients,10,16 and have been used to 
compare progression of liver fibrosis between HCV-positive and HCV-negative patients in 
the Veterans’ Affairs health care system.11,12 Likewise, FIB4 and APRI have been used as 
end points for post-treatment and post-SVR outcomes in HCV and human 
immunodeficiency virus (HIV)/HCV co-infected patients.
We investigated the impact of HCV treatment therapy on longitudinal change of FIB4 values 
collected across 10 years of follow-up evaluation in a subset of HCV-infected patients from 
CHeCS.13
Materials and Methods
Chronic Hepatitis Cohort Study
CHeCS is a retrospective/prospective, observational multicenter study that includes hepatitis 
patients from 4 large US health systems; the study design and execution have been described 
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previously.14,15 CHeCS follows US Department of Health and Human Services guidelines 
for the protection of human subjects; protocols were approved by the institutional review 
boards at each site. Briefly, electronic administrative claims data and electronic health 
records (EHRs) for HCV patients age 18 years and older who received health services at any 
study site between January 1, 2006, and December 31, 2013, were used to identify study 
candidates; eligibility was confirmed during medical chart abstraction. To reflect a real-
world setting, patients were excluded if they had participated in a clinical trial of HCV 
antiviral therapy or were co-infected with hepatitis B; HIV co-infected patients remained 
eligible for inclusion.
For each patient, observation commenced at the index date. For treated patients, this was 
defined as the date of first treatment initiation. For untreated patients, an automated 
computer algorithm using a frequency-matched approach was used to select index dates at or 
after the HCV diagnosis date (the earliest date of an HCV-associated diagnosis code and/or a 
positive laboratory test in the patient’s medical records). We also performed a sensitivity 
analysis by substituting the last treatment initiation date for the index date to include prior 
treatment experience at baseline. Patients receiving ongoing HCV treatment without 
sufficient follow-up evaluation or those who received a liver transplant before their index 
date were excluded.
Outcome
We used the FIB4 score as the outcome of interest and APRI for the sensitivity analysis, 
calculated using the following formulas:
We used laboratory tests collected within 7 days of one another and patient age at the time of 
laboratory assessment. Aminotransferase levels and platelet counts measured during 
antiviral therapy were excluded because therapy can influence these parameters.16 The FIB4 
score and APRI were summarized using a median smoother for every 90-day interval. 
Because of non-normality, data were log-transformed. Patients with at least 2 FIB4 intervals 
after the index date were included in the analysis.
Control Variables at Index Date
Demographic information included age, sex, race/ ethnicity, estimated median annual 
household income, and insurance status at index date. Racial/ethnic classifications included 
Native American, Asian, black, white, or Pacific Islander/Hawai’ian. For analytic purposes, 
Asian and Pacific Islander/Hawai’ian was considered a single group. Insurance status 
(insured/not insured) was classified by the encounter nearest the index date. Consistent with 
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our published results,14 income was categorized using US Census variable P053001.17 Index 
year was used as a baseline control variable.
A subset of commonly known risk factors (age, sex, race, HCV genotype [GT], Charlson/
Deyo index [calculated from inpatient, outpatient, and claims data for 12 months before the 
index date], diabetes diagnosis, and recent drug/alcohol abuse) were selected as covariates to 
study the effect of HCV treatment on progression of liver fibrosis. Additional variables were 
included in the analysis to adjust for possible confounding owing to treatment selection bias. 
Clinical data captured before and at index included comorbid conditions,18 HIV co-
infection, and laboratory testing. We also used International Classification of Diseases, 9th 
revision diagnostic and procedure codes as well as Current Procedural Terminology-version 
4 procedure codes to assess possible contraindications to antiviral therapy (Supplementary 
Table 1).
Anti–Hepatitis C Virus Therapy and Response
Detailed antiviral medication data (drug name, start/ stop dates) were collected via chart 
abstraction at or after the index date. Combination therapy was identified when multiple 
hepatitis drugs were administered concomitantly. Data on routine HCV RNA quantification 
tests were obtained via the EHR. Patients were classified as having achieved SVR if 
laboratory tests collected 12 weeks or more after therapy showed undetectable viral RNA 
loads; otherwise they were classified as having treatment failure (TF). Treatment status 
(SVR, TF, or untreated) was considered a time-varying covariate.
Statistical Analysis
We hypothesized that liver fibrosis would change over time, and that changes would be 
associated with antiviral HCV therapy as well as known risk factors. Before our analysis, 
however, we assessed possible selection bias for receipt of antiviral therapy. If bias was 
present, we used a weighted propensity-score method to adjust for differences between 
patients who had or had not received antiviral therapy. This method included logistic 
regression modeling of the controlling baseline covariates. Patient data were weighted based 
on the inverse propensity to receive/not receive antiviral therapy (the IPTW approach).19 
Covariate balance was checked after adjustment.
We then examined the effects of treatment and time on FIB4 progression (in a natural log 
scale) using mixed models with specific covariance patterns for longitudinal data, adjusted 
by IPTW. Specifically, the trajectory of FIB4 for each individual was modeled as a function 
of time and of time-varying patient treatment group variables. Time was treated as a nominal 
class variable. We considered a variety of covariance structures, including directly-specified 
compound symmetry, autoregressive with/without heterogeneous variances, and indirectly 
specified structures, based on random coefficients in time. Any variable with individual 
(univariate) effects on the change in FIB4 was a candidate for the initial model. We used the 
Bayesian Information Criterion (BIC) to assess the models’ goodness-of-fit. The final model 
retained variables that significantly contributed to differentiation of FIB4 trajectories with 
the lowest (ie, best-fitting) BIC scores.
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We also tested treatment-by-risk factor (covariate) interactions, followed by further 
evaluation of quantitative interactions (magnitude but not direction of response varies by the 
presence/absence of the risk factor) or qualitative interaction (change in direction of 
response; eg, a treatment benefits the young but harms the old).20 All interactions were 
quantitative; because they did not contribute to goodness-of-fit and could potentially 
complicate the models, they were dropped from the final analysis.
Four sensitivity analyses were conducted, as follows: (1) APRI as the outcome of interest, 
owing to the inclusion of age in the formula for calculating FIB4 and thus high correlation 
between these; (2) substitution of last treatment initiation date for index date, owing to 
patients receiving more than one course of treatment; (3) a 1-to-1 (treated and untreated) 
matched cohort to match controls at baseline; and (4) omission of several important 
treatment selection or prognostic variables (eg, baseline fibrosis, covariates related to 
treatment contraindications) for propensity score calculation. In the last sensitivity analysis, 
we tested the treatment group effect to determine whether it had changed; a robust treatment 
effect indicates that unobserved confounding can be disregarded.21
Results
We identified 6975 CHeCS patients with confirmed HCV infection and a baseline FIB4 
measurement. We excluded 2244 of these patients: 144 were enrolled in a clinical trial; 74 
had HCV treatment/SVR outside of the CHeCS systems; 254 had ongoing therapy; 75 had 
hepatitis B virus co-infection; and 1709 had insufficient follow-up evaluation (<2 time 
points). In total, 4731 patients were included in the analysis. Of these, 1657 (35%) were 
treated; 1367 (82%) received 1 course of therapy, and 290 received more than 1 course. The 
median course duration was 11 months. Of the 1657 treated patients, 755 (46%) achieved 
SVR. Laboratory follow-up periods ranged from less than 180 days to more than 10 years.
Patient Characteristics at Baseline
Table 1 describes our sample. Asian patients were over-represented (6%) because of the 
participation of a large health care system in Hawai’i. Notably, at baseline roughly half 
(2290; 48%) of all patients had advanced fibrosis; patients with and without advanced 
fibrosis received antiviral treatment at the same rate (35%). The median time from initial 
indication of HCV infection/ diagnosis to initiation of antiviral treatment was approximately 
2 years; the interquartile range (25%–75%) was 1 to 7 years.
Antiviral HCV Treatment Allocation
In unadjusted comparisons, untreated patients were older, more likely to have a history of 
substance abuse, and more likely to be black than untreated patients (Table 1). Untreated 
patients also had higher comorbidity scores, were less likely to have insurance, and had 
lower median household incomes. A larger proportion of treated patients had an abnormal 
alanine aminotransferase result at baseline. After propensity-score adjustment, demographic 
and clinical characteristics were balanced between treatment groups (Table 1).
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Final Model: Factors Impacting Fibrosis Trajectory
The final model with an autoregressive covariance pattern and time as a nominal variable 
showed the best data fit. Descriptive analyses indicated the following: (1) change in FIB4 
was nonlinear and varied by individual; and (2) treatment impact was time-dependent 
(treatment-by-time interaction with P value < .0001) (Table 2). The basic model with an 
autoregressive covariance pattern was selected for further examination, given evidence of 
superior fit. Race, sex, baseline FIB4 score, and hepatitis genotype were retained in the final 
model, resulting in improved fit (BIC 18,442) compared with the unadjusted model (BIC 
21,125). Sensitivity analysis showed a similar trend in treatment effects and post-treatment 
group-by-time interaction (detailed later).
Impact of Hepatitis C Antiviral Therapy and Sustained Virological Response on Liver 
Fibrosis Progression
Figure 1 shows 4 representative trajectories from our sample. Patient A did not achieve SVR 
until completion of a third course of therapy, approximately 5 years after the first treatment 
initiation. Patient B achieved SVR after the first course of treatment. Notably, FIB4 
decreased after SVR in both patients, consistent with the findings of the French national 
prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH) 
Cohort investigators.12 Furthermore, this reduction continued long term, suggesting possible 
regression of fibrosis. Conversely, patients C (untreated) and D (treatment failure) showed 
upward trends in FIB4 score.
Figure 2A presents the observed mean trajectories of FIB4 (in log scale) by treatment group. 
A cut-off value of 1.81 (0.59 after log transformation) is presented as a reference; this cut-
off value was validated previously in this cohort to predict advanced fibrosis.22 At baseline, 
1657 patients had received treatment and 3074 patients were untreated. The first SVR 
occurred at interval 3 (24 weeks after treatment initiation) in 68 patients. At the end of the 
follow-up period, 755 treated patients had achieved SVR.
Figure 2B presents the final model estimates of FIB4 trajectories by treatment group (Table 
2), which showed patterns similar to those of the observed data. As shown in Figure 2B, 
predicted FIB4 in patients who achieved SVR (Figure 2B, uneven dashed line) can be 
broken up into 3 phases: (1) decrease; (2) plateau; and (3) increase. FIB4 started higher than 
1.81 and sharply decreased, remaining lower than 1.81 from years 2 to 5, when a gradual 
increase began. At 77 weeks after treatment initiation, this decrease became significantly 
different from baseline (0.25; 22% on original scale; P < .0001). We noted that a few 
patients showed a late increase, likely because missing FIB4 values resulted in a wide 
confidence interval for the predicted results. FIB4 in the SVR group was consistently lower 
over time than in the untreated or TF groups (P < .05). In untreated patients, FIB4 gradually 
increased; in year 2, the increase became statistically significant (increased by 11%; P = .
013). By year 5, FIB4 had increased by 44% (P < .0001) compared with baseline.
Sensitivity analyses showed similar effects of treatment on APRI trajectories (Figure 3). 
APRI remained significantly lower in SVR patients than in untreated or TF patients. Similar 
treatment trajectories were observed using the last treatment initiation date as the index date, 
Lu et al. Page 6
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2017 December 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
with follow-up evaluation limited to 6 years (data not shown). We also observed a consistent 
treatment effect in our 1:1 matched cohort (Supplementary Figure 1), as well as in analyses 
that omitted several key covariates for the calculation of propensity scores (Supplementary 
Figure 2).
Additional Risk Factors for Liver Fibrosis Progression
Across time (Table 2), men showed consistently higher FIB4 levels than women (coefficient 
= 0.05; P < .001), and black patients presented with lower FIB4 than white patients 
(coefficient = −0.11; P < .001). GT 1 and 3 patients had higher FIB4 scores than GT 2 
patients; although GT 3 patients showed lower FIB4 than GT 1 patients, the difference was 
not significant (coefficient = 0.04; P = .19). We noted that patients with lower baseline FIB4 
scores (<1.81) tended to remain low over time (P < .001). Age remained an important risk 
factor; older age at baseline was associated with a higher FIB4 over time. No qualitative risk 
factor-by-treatment interaction was detected, indicating that risk factor effects were 
consistent among the treatment groups.
Overall Risk Profile for Liver Fibrosis Progression
In Table 2, patients’ FIB4 trajectories were classified into subgroups based on combinations 
of risk factors and treatment status, which is shown in Figure 4. FIB4 growth patterns among 
treatment groups were similar to those described in Figure 2B. Older patients (>60 y) 
showed consistently higher FIB4 than younger patients (≤40 y). Interestingly, white male 
patients with HCV GTs 1 or 3 showed the highest FIB4 levels in each of the 3 treatment 
groups, whereas black female patients with HCV GT 2 had the lowest FIB4 levels.
Discussion
This study investigated the longitudinal progression of FIB4 in a real-world sample of more 
than 4000 HCV patients. In propensity score–adjusted analyses, we observed significant 
longitudinal changes in FIB4 that varied by treatment status. In successfully treated patients, 
SVR appears to induce long-term regression of fibrosis; in contrast, the absence of treatment 
and treatment failure were characterized by progressively increasing FIB4 levels. These 
findings provide further evidence for the applicability of repeated measures of FIB4 in HCV-
infected patients.
Initial FIB4 values were lower among patients who achieved SVR; these values continued to 
decrease and then remained stable through the years. Although FIB4 increased slightly after 
year 5, these changes were likely due to fewer data points and inclusion of patient age in the 
formula; this was confirmed using APRI, which is calculated without age (Figure 3B). 
Untreated patients and patients with treatment failure showed increasing FIB4 over time, and 
values for both groups remained higher than 1.81.
Our finding that FIB4 trajectory decreases after SVR is consistent with smaller histologic 
studies.1–4 A significant regression of fibrosis has been observed previously among hepatitis 
B patients after long-term virologic suppression with tenofovir disoproxil fumate.23 
Although the exact mechanism is unclear, suppression of viral replication may reduce 
hepatic inflammation and consequent fibrosis, allowing regeneration of healthy tissue. 
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Notably, SVR patients showed flat FIB4 trajectories despite increasing age—suggesting 
stability of fibrosis or possibly fibrotic regression. The consistent results from our sensitivity 
analyses further validate these findings. Although APRI changes appeared to be more stable, 
FIB4 has significantly higher predictive ability for liver fibrosis (P < .0001)9; future analyses 
may use hidden Markov modeling to permit consideration of a range of clinical conditions, 
or include markers developed from laboratory results and liver-related diagnosis codes 
(International Classification of Diseases, 9th revision codes).
Our results showed that FIB4 trajectories varied based on factors such as sex, race, 
genotype, baseline FIB4, age, as well as treatment/response groups. Patients infected with 
HCV GTs 1 or 3 (Figure 4, thick lines) showed significantly higher FIB4 levels and steeper 
FIB4 trajectories across all time points and in each of the 3 treatment groups than patients 
with GT 2. Although there were no significant differences between GTs 1 and 3 trajectories, 
GT 3 patients showed a relatively lower FIB4 (coefficient = 0.04; P = .19).
In addition, patients in any of the 3 treatment groups with a FIB4 less than 1.81 at the index 
date remained below this cut-off value throughout follow-up evaluation (Figure 4). White 
patients also presented with a higher FIB4 than black patients; likewise, older age at baseline 
was a risk factor for higher FIB4 over time. Men consistently showed higher FIB4 over time 
than women. Although HIV co-infection, diabetes mellitus, and substance abuse (including 
alcohol) were individual risk factors for FIB4 progression, the effects diminished after 
adjustment for other covariates. Notably, risk factor effects were consistent among the 
treatment groups, indicating that treatment status remained the most important influence on 
FIB4 trajectories.
Our study had some limitations. The calculation of FIB4 uses patient age at the time of 
laboratory assessment, thus longitudinal FIB4 measures tend to increase over time, even 
with unchanged laboratory parameters. Also, because of our reliance on electronically 
collected observational data as well as inclusion of patients from the early 1990s forward, 
our ability to calculate the index date body mass index and to include detailed alcohol 
consumption data were limited. Another limitation of this study was that the duration of 
HCV infection in this population was estimated. However, we used several levels of data to 
confirm the date of diagnosis or first indication of infection, prioritized in the following 
order: (1) patient self-report; (2) medical chart abstraction; (3) HCV medication 
prescriptions or fills extracted from the EHR; and (4) diagnosis and procedure codes from 
the EHR. Patients with acute HCV were excluded from the cohort. We also found that 
unadjusted clinical profiles and propensity scores differed between the treated and untreated 
groups, although adjustment using IPTW (based on 43 covariates collected at baseline) 
resulted in excellent balance between the 2 groups. Likewise, our sensitivity analysis, which 
omitted several treatment-selection and prognostic covariates, showed consistent treatment 
group effects. We are confident in our estimated treatment effects and that unobserved 
confounding has not influenced our results.21
Despite the considerable progress in the development of noninvasive methods to assess liver 
fibrosis, none is widely accepted yet as an equivalent to liver biopsy. The decrease observed 
in serum biomarker values in the present study may not always represent a reversal of 
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histologic fibrosis. However, many recent studies indeed have shown that improvement in 
serum markers correlates with decreasing fibrosis stage.10,12,16
Both our own and other large cohort studies have shown the clinical benefits of SVR after 
HCV antiviral therapy, including a reduction in all-cause mortality. Such findings suggest a 
regression of fibrosis. By using a biomarker for liver fibrosis previously validated in a static 
setting, we now expand on smaller studies and show that this marker can be used 
successfully for longitudinal analyses. Based on the present analysis of FIB4 trajectories 
across 10 years in a large, racially diverse sample of HCV patients receiving routine care, 
our findings strongly suggest that patients who achieve SVR likely show a sustained 
regression of hepatic fibrosis.
Supplementary Material
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Figure 1. 
Four individual trajectories of logFIB4 across 10 years of follow-up evaluation. Data were 
smoothed by the B-spline method (thick lines).
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Figure 2. 
Average observed (top) and predicted (bottom) logFIB4 from an unadjusted model with 95% 
confidence bands (shaded) over 10 years by treatment group. (A) Treatment failure and (B) 
untreated patients were compared at each time interval. *Significant difference between 
treatment failure and untreated patients at a specific time interval (P < .05). The number of 
patients at each time point is noted at the bottom.
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Figure 3. 
Average observed (top) and predicted (bottom) logAPRI with 95% confidence bands 
(shaded) over 41 intervals of 90 days by group. Treatment failure and untreated patients 
were compared at each time interval. *Significant difference between treatment failure and 
untreated patients at a specific time interval (P < .05). The number of patients at each time 
point is noted at the bottom.
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Figure 4. 
Predicted average trajectories of logFIB4 over 10 years by group (baseline FIB4, HCV GT, 
sex, and race) for patients 40 years or younger vs older than 60 years. Thick lines, GT 1 or 3 
patients; thin lines, GT 2 patients; solid lines, women; dashed lines, men; black lines, black 
patients; gray lines, white patients. Lines are stratified by baseline FIB4 levels (top, >1.81; 
bottom, ≤1.81). The expected trajectory for black female GT 1 patients overlaps with the 
trajectory for white male GT 2 patients.
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Table 2
Parameter Estimates and Model Fitting Results for logFIB4 Over Time
Unadjusted model Adjusted model
Parameter Estimate P value Estimate P value
Intercept 0.61 <.001 0.35 <.001
Interval (time) a <.001 a <.001
Treatment group effect <.001 <.001
Treatment-by-time interaction <.001 <.001
FIB4 at baseline: 1.07 <.001
 >1.81 vs ≤1.81
Genotype
 1 vs 2 0.26 <.001
 3 vs 2 0.33 <.001
 Other/unknown vs 1 0.20 <.001
Race
 Asian/other vs white −0.03 .375
 Black vs white −0.11 <.001
Age, y
 <40 vs ≥60 −0.69 .034
 40 to <50 vs ≥60 −0.19 .029
 50 to <60 vs ≥60 −0.06 .027
Sex, male vs female 0.05 <.001
Akaike information criterion 24,894.4 21,134.3
BIC or Schwarz criterion 24,907.3 21,147.2
NOTE. Unadjusted model: logFIB4 over time by treatment group only. Adjusted model: logFIB4 over time by treatment group adjusted for 
baseline covariates.
a
Detailed estimates of treatment and SVR effects at each interval are shown in Figures 2 and 3.
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2017 December 12.
